Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NoGo in Overactive Bladder
NCT04357223Phase 2Unknown
- Sponsor
- SagaNatura
- Start
- May 2020
- Primary completion
- Feb 2021
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial (2 arms), sponsored by SagaNatura. Primary endpoint: Reduction of urination frequency at 6 weeks. Status: unknown.
Beyond the preview
Go deeper on NCT04357223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04357223.